VivoSeq
Oncology

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

6

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma is an early-stage landscape with 6 programs across 3 companies. The most active players are Avyxa, Johnson & Johnson, Gilead.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody125%
Antibody–drug conjugate125%

Modality classified for 67% of 6 pipeline programs.

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy
Not yet recruiting·National Cancer Institute (NCI)·Phase 2·NCT07504588·87 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)